Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
4D Molecular Therapeutics’ $120 Million Common Stock Offering
Merck’s Acquisition of Prometheus Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
Sonoma Biotherapeutics’ Collaboration Agreement with Regeneron Pharmaceuticals
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
dbt Labs’ Acquisition of Transform Data
Latham & Watkins advised dbt Labs on the deal. dbt Labs announced that it has signed a definitive agreement to acquire Transform Data Inc. The acquisition...
OPEN Health’s Acquisition of Acsel Health
Latham & Watkins LLP represented Astorg and OPEN Health in the transaction. OPEN Health, a portfolio company of European private equity firm Astorg, announced the acquisition of...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...
Carenet Health’s $45 Million Acquisition of Stericycle’s Communication Solutions Business
Latham & Watkins LLP represented Stericycle in the transaction. Stericycle, Inc. (Nasdaq: SRCL), a leading provider of regulated medical waste management and secure information destruction solutions,...
Indivior’s $145 Million Acquisition of Opiant Pharmaceuticals
Covington & Burling LLP advised Indivior, while Latham & Watkins LLP represented Opiant in the transaction. Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has entered into a definitive...
Kindeva Drug Delivery’s Combination With Meridian Medical Technologies
Kirkland & Ellis and ArentFox Schiff advised Altaris on the deal. Latham & Watkins represented the lenders on the financing aspects. Altaris, LLC, a healthcare investment...
Merck’s $1.35 Billion Acquisition of Imago BioSciences, Inc.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
LG Chem’s Acquisition of AVEO Oncology
Latham & Watkins LLP represented LG Chem in the transaction, while WilmerHale LLP represented AVEO. LG Chem, Ltd. (KOSPI: 051910) entered into a definitive agreement to acquire...